Drugs / AS03-adjuvanted H1N1 pandemic influenza vaccine
AS03-adjuvanted H1N1 pandemic influenza vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT01016548 | Nov 2009 → Mar 2010 | plasma cell myeloma, swine influenza | University Health Network, Toronto | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AS03-adjuvanted H1N1 pandemic influenza vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01016548 ↗ |
| Modality | Vaccine | “approved adjuvanted vaccine” NCT01016548 ↗ |
| Route | Intramuscular | “via the intramuscular route” NCT01016548 ↗ |